Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Catalent invests over $27 million to commercialize Zydis Ultra

cphi-onlineMarch 12, 2019

Tag: Catalent , Zydis Ultra , oral disintegrating tablet , ODTs

PharmaSources Customer Service